Prognostic value of programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
暂无分享,去创建一个
Hongwei Li | Peng Cai | Lei Zhang | Hongmei Yin | Qun Zhang | Chaomang Zhu | Duo-jie Li | Feng Li
[1] J. Bergh,et al. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data , 2019, Clinical Cancer Research.
[2] W. Guo,et al. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. , 2019, Human pathology.
[3] J. Shang,et al. High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy , 2018, Oncology letters.
[4] Duck-Woo Kim,et al. Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis , 2018, Cancer science.
[5] Hongwei Zhang,et al. PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma , 2018, Journal of Cancer.
[6] H. Baba,et al. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer , 2017, Annals of surgery.
[7] Y. Doki,et al. MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. , 2017, Oncology letters.
[8] Haitao Ma,et al. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients. , 2017, Clinica chimica acta; international journal of clinical chemistry.
[9] Ping Wang,et al. Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor , 2017, Cancer science.
[10] E. Oki,et al. PD-L1 expression at tumor invasive front is associated with EMT and poor prognosis in esophageal squamous cell carcinoma. , 2017 .
[11] S. Motoyama,et al. PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. , 2017, Anticancer research.
[12] Jianming Xu,et al. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma , 2017, Oncotarget.
[13] Yingyong Hou,et al. Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma , 2016, Oncotarget.
[14] Minghui Zhang,et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients , 2016, Scientific Reports.
[15] C. Kang,et al. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma , 2016, World journal of gastroenterology.
[16] K. Mimori,et al. Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome , 2016, Annals of Surgical Oncology.
[17] S. Nomura,et al. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma , 2016, Oncotarget.
[18] Guosheng Feng,et al. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. , 2015, International journal of clinical and experimental medicine.
[19] Chengming Sun,et al. The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis , 2015, OncoTargets and therapy.
[20] Jie He,et al. Annual report on status of cancer in China, 2011. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[21] Lieping Chen,et al. Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation , 2014, Cancer journal.
[22] W. Mao,et al. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? , 2012, World Journal of Surgical Oncology.
[23] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[24] M. Azuma,et al. Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.
[25] Sin-Ho Jung,et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. , 2016, European journal of cancer.
[26] C. Marquette,et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] F. Bosman,et al. WHO Classification of Tumours of the Digestive System , 2010 .
[28] M. Lefranc,et al. The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. , 2009, Molecular immunology.
[29] J R Siewert,et al. Esophageal Carcinoma , 2000, Recent Results in Cancer Research.